Azafaros Scoops €132M in Series B to Accelerate Drug Trials
Deal News | May 13, 2025 | Biogeneration Ventures (BGV)
Azafaros, a portfolio company of Biogeneration Ventures (BGV), has secured €132 million in an oversubscribed Series B financing round. The substantial funding will be used to advance its Phase 3 clinical programs focusing on innovative therapies for lysosomal storage disorders. With this capital infusion, Azafaros is well-positioned to progress its clinical trials and expedite the development of treatments that could have significant impacts on patients with these rare diseases. BGV, as the backing private equity firm, underscores its commitment to advancing revolutionary healthcare solutions for critical conditions.
Sectors
- Biotechnology
- Healthcare
- Private Equity
Geography
- Netherlands – Biogeneration Ventures (BGV) is based in the Netherlands, indicating its geographical focus.
- Europe – The financial movement and clinical advancements involving Azafaros position the company within the wider European biotech and healthcare landscape.
Industry
- Biotechnology – The article discusses Azafaros' advances in clinical programs focusing on lysosomal storage disorders, indicative of the biotechnology industry.
- Healthcare – The focus on developing therapies for lysosomal storage disorders positions the companies within the broader healthcare sector.
- Private Equity – Biogeneration Ventures (BGV) is a private equity firm involved in financing Azafaros, highlighting its role within this investment industry.
Financials
- €132M – The amount raised by Azafaros in its oversubscribed Series B financing round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Azafaros | Target Company | Company | A biotech company working on innovative therapies for lysosomal storage disorders. |
| Biogeneration Ventures (BGV) | PE Firm | Company | A private equity firm that backs biotechnology and life sciences companies. |